Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine and TBI conditioning in AML and MDS
NCT04861207Phase 2Active, not recruiting
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Oct 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Started Oct 2021; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04861207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861207.